Trial Profile
An Investigator-and-subject Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Repeat Doses Of Pf-06648671 In Healthy Adult Subjects And Healthy Elderly Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PF 6648671 (Primary) ; Midazolam
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Jul 2019 PKPD model was developed to characterize the differential effects of PF 06648671 on the various CSF species in healthy humans using data from three phase I studies (NCT02316756, NCT02440100 and NCT02407353 ); results published in the Clinical Pharmacology and Therapeutics
- 20 Jul 2017 Results of 3 phase 1 studies assessing plasma exposure and cerebrospinal fluid response relationship in healthy subjects, presented at the Alzheimer's Association International Conference 2017.
- 08 Nov 2016 Status changed from recruiting to completed.